Literature DB >> 17562697

The neuropharmacology of psychosis.

Carol A Tamminga1, John M Davis.   

Abstract

Antipsychotic drugs (APDs) are therapeutic in psychotic disorders. They are not specific treatments for schizophrenia (SZ) but useful in bipolar disorder (BD), psychotic depression, Alzheimers disease, and other psychotic diagnoses. In this perspective, we discuss the actions of APDs for the treatment of both SZ and bipolar-1 disorder (BD-1) with a specific focus on the implications of these data for the whole group of psychotic diagnoses. Both schizophrenic and BD-1 are characterized by several symptom dimensions, some overlapping and some distinctive. We discuss a dimensional approach to the diagnosis of BD and SZ and suggest that psychosis is an important dimension of each. In order to define the dimension of psychosis more carefully would require additional research to fill in the gaps in our knowledge. We propose that psychosis is a dimension that cuts through many psychiatric disorders, and the use of this dimension may be useful for clinical and research progress. We discuss the kinds of data necessary to further support the dimensional aspects of psychosis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17562697      PMCID: PMC2632319          DOI: 10.1093/schbul/sbm063

Source DB:  PubMed          Journal:  Schizophr Bull        ISSN: 0586-7614            Impact factor:   9.306


  63 in total

1.  Medicine. What are the right targets for psychopharmacology?

Authors:  Steven E Hyman; Wayne S Fenton
Journal:  Science       Date:  2003-01-17       Impact factor: 47.728

Review 2.  New treatments for bipolar disorder: the role of atypical neuroleptic agents.

Authors:  S N Ghaemi
Journal:  J Clin Psychiatry       Date:  2000       Impact factor: 4.384

3.  Amisulpride, an unusual "atypical" antipsychotic: a meta-analysis of randomized controlled trials.

Authors:  Stefan Leucht; Gabi Pitschel-Walz; Rolf R Engel; Werner Kissling
Journal:  Am J Psychiatry       Date:  2002-02       Impact factor: 18.112

4.  Gabapentin in bipolar disorder: a placebo-controlled trial of adjunctive therapy. Gabapentin Bipolar Disorder Study Group.

Authors:  A C Pande; J G Crockatt; C A Janney; J L Werth; G Tsaroucha
Journal:  Bipolar Disord       Date:  2000-09       Impact factor: 6.744

Review 5.  The endophenotype concept in psychiatry: etymology and strategic intentions.

Authors:  Irving I Gottesman; Todd D Gould
Journal:  Am J Psychiatry       Date:  2003-04       Impact factor: 18.112

6.  The McLean-Harvard first-episode project: 6-month symptomatic and functional outcome in affective and nonaffective psychosis.

Authors:  M Tohen; S M Strakowski; C Zarate; J Hennen; A L Stoll; T Suppes; G L Faedda; B M Cohen; P Gebre-Medhin; R J Baldessarini
Journal:  Biol Psychiatry       Date:  2000-09-15       Impact factor: 13.382

7.  Basal ganglia GABAA and dopamine D1 binding site correlates of haloperidol-induced oral dyskinesias in rat.

Authors:  O Shirakawa; C A Tamminga
Journal:  Exp Neurol       Date:  1994-05       Impact factor: 5.330

8.  Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials.

Authors:  Stephen R Marder; Robert D McQuade; Elyse Stock; Stephen Kaplita; Ronald Marcus; Allan Z Safferman; Anutosh Saha; Mirza Ali; Taro Iwamoto
Journal:  Schizophr Res       Date:  2003-06-01       Impact factor: 4.939

9.  Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder.

Authors:  John M Kane; William H Carson; Anutosh R Saha; Robert D McQuade; Gary G Ingenito; Dan L Zimbroff; Mirza W Ali
Journal:  J Clin Psychiatry       Date:  2002-09       Impact factor: 4.384

Review 10.  New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis.

Authors:  Stefan Leucht; Kristian Wahlbeck; Johannes Hamann; Werner Kissling
Journal:  Lancet       Date:  2003-05-10       Impact factor: 79.321

View more
  4 in total

Review 1.  Comparing genes and phenomenology in the major psychoses: schizophrenia and bipolar 1 disorder.

Authors:  Elena Ivleva; Gunvant Thaker; Carol A Tamminga
Journal:  Schizophr Bull       Date:  2008-05-30       Impact factor: 9.306

2.  Reduced expression of G protein-coupled receptor kinases in schizophrenia but not in schizoaffective disorder.

Authors:  E R Bychkov; M R Ahmed; V V Gurevich; J L Benovic; E V Gurevich
Journal:  Neurobiol Dis       Date:  2011-07-20       Impact factor: 5.996

Review 3.  The evolution of drug development in schizophrenia: past issues and future opportunities.

Authors:  William T Carpenter; James I Koenig
Journal:  Neuropsychopharmacology       Date:  2007-11-28       Impact factor: 7.853

4.  Characteristics of subjects with comorbidity of symptoms of generalized anxiety and major depressive disorders and the corresponding threshold and subthreshold conditions in an Arab general population sample.

Authors:  Jude U Ohaeri; Abdel W Awadalla
Journal:  Med Sci Monit       Date:  2012-03
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.